Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults

被引：10

作者：

Patruno, Cataldo ^{[1
]}

Stingeni, Luca ^{[2
]}

Hansel, Katharina ^{[2
]}

Ferrucci, Silvia Mariel ^{[3
]}

Tavecchio, Simona ^{[4
]}

Fabbrocini, Gabriella ^{[5
]}

Nistico, Steven Paul ^{[1
]}

Foti, Caterina ^{[6
]}

De Prezzo, Serena ^{[6
]}

Napolitano, Maddalena ^{[7
]}

机构：

[1] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Viale Europa, I-88100 Catanzaro, Italy

[2] Univ Perugia, Dept Med, Dermatol Sect, Perugia, Italy

[3] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Dermatol Sect, Milan, Italy

[4] Univ Milan, Dept Physiopathol & Transplantat, Milan, Italy

[5] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Naples, Italy

[6] Univ Bari, Dermatol Clin, Dept Biomed Sci & Human Oncol, Bari, Italy

[7] Univ Molise, Dept Hlth Sci Vincenzo Tiberio, Campobasso, Italy

来源：

DERMATOLOGIC THERAPY | 2020年 / 33卷 / 03期

关键词：

adult atopic dermatitis; dupilumab; nummular eczema; phenotype; ALLERGY;

D O I：

10.1111/dth.13290

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Nummular eczema (NE) is currently considered as one of the clinical phenotypes of atopic dermatitis (AD) of the adult. In this multicentre study, 30 adult patients (age >= 18 years) affected with nummular-like AD were treated with dupilumab, a monoclonal antibody against the receptor for interleukin(IL)-4 and IL-13. The evaluation of the results after 16 weeks of treatment showed a significant improvement of the disease, as demonstrated by reduction in Eczema Area Severity Score (EASI), visual analogue score (VAS) of pruritus, and Dermatology Life Quality Index (DLQI) scores. Conjunctivitis in one patient was the only side effect. In conclusion, dupilumab seems to be an effective and safe treatment in NE phenotype of AD of the adult.

引用

页数：3

共 50 条

[1] Effectiveness of dupilumab in pediatric patients with a nummular phenotype of atopic dermatitis
Kim, Eun Jae
Hlobik, Madeline
Ho, Tina
[J]. PEDIATRIC DERMATOLOGY, 2024, 41 (03) : 455 - 457
[2] Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis
Napolitano, Maddalena
Fabbrocini, Gabriella
Scalvenzi, Massimiliano
Nistico, Steven Paul
Dastoli, Stefano
Patruno, Cataldo
[J]. DERMATITIS, 2020, 31 (01) : 81 - 84
[3] Effectiveness of dupilumab in atopic dermatitis
Romero Puerto, J.
Garcia Marin, J.
Fages Perez, M.
Martinez-Echevarria Gil-Delgado, Z.
Moreno Herrera, A.
[J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (06) : 1555 - 1555
[4] Clinical study on the significance and the frequency of atopic dermatitis in nummular eczema
Cho, SH
Kim, JW
Park, CW
Ro, YS
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 121 (05) : 1263 - 1263
[5] Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema
Jarvikallio, A
Harvima, IT
Naukkarinen, A
[J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 2003, 295 (01) : 2 - 7
[6] Cost-effectiveness analysis of dupilumab for the treatment of severe atopic dermatitis in adults in Italy
Costanzo, Antonio
Furneri, Gianluca
Bitonti, Rossella
Pedone, Maria Paola
Fanelli, Francesca
Di Turi, Roberta
[J]. GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2020, 7 (01) : 57 - 65
[7] Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema
Anitta Järvikallio
Ilkka T. Harvima
Anita Naukkarinen
[J]. Archives of Dermatological Research, 2003, 295 : 2 - 7
[8] Dupilumab treatment of nummular dermatitis: A retrospective cohort study
Choi, Sara
Zhu, Gefei A.
Lewis, Matthew A.
Honari, Golara
Chiou, Albert S.
Ko, Justin
Chen, Jennifer K.
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (05) : 1252 - 1255
[9] Effectiveness of Dupilumab in the treatment of both atopic dermatitis and alopecia universalis
Call, John E.
Sahni, Sakshi
Zug, Kathryn A.
[J]. CLINICAL CASE REPORTS, 2020, 8 (08): : 1337 - 1339
[10] Dupilumab for treatment of atopic dermatitis
Seegraeber, Marlene
Srour, Jerome
Walter, Alexandra
Knop, Macarena
Wollenberg, Andreas
[J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (05) : 467 - 474

← 1 2 3 4 5 →